Related Experiment Video
Updated: Aug 14, 2026
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Extensive small-cell lung cancer: a treatment overview
1Thoracic Oncology, Vanderbilt University, Nashville, Tennessee, USA.
Oncology (Williston Park, N.Y.)
|September 12, 2000
Summary
Small-cell lung cancer (SCLC) has poor long-term survival despite chemotherapy. Current treatments, including maintenance chemotherapy and dose escalation, show no significant survival advantage for SCLC patients.
Area of Science:
- Oncology
- Medical Research
Background:
- Small-cell lung cancer (SCLC) accounts for approximately 25% of new lung cancer cases.
- Despite initial response to chemotherapy, long-term survival for SCLC patients remains poor (around 10%).
Purpose of the Study:
- To review the current efficacy of chemotherapy regimens for small-cell lung cancer.
- To identify limitations in existing treatment strategies and explore potential future directions.
Main Methods:
- Literature review of studies on chemotherapy for small-cell lung cancer.
- Analysis of survival data related to maintenance chemotherapy, dose escalation, and specific chemotherapeutic agents.
Main Results:
- Maintenance chemotherapy has not demonstrated a significant survival advantage in SCLC.
- Chemotherapy appears effective for a limited duration (4-6 cycles) with no defined role for dose escalation.
- Single-agent etoposide may be less effective than combination intravenous chemotherapy for extensive SCLC.
Conclusions:
- Current chemotherapy approaches offer limited long-term survival benefits for SCLC.
- Further research is needed to identify more effective treatments, including novel agents.
- Optimal treatment strategies for SCLC require further investigation and development.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...